BioCryst Pharma (BCRX) Tops Q4 EPS by 1c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.31 +1.86%
Revenue Growth %: +13.7%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +13.7%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.25), $0.01 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $6.34 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Qualcomm investor day to detail data center plans Wednesday
- Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
